Pioglitazone: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 50: | Line 50: | ||
! | ! | ||
|- | |- | ||
! Equivalent | ! Equivalent Dosage (mg) | ||
! | ! | ||
! | ! | ||
Revision as of 07:21, 11 November 2010
|
Better Known as: Actos
- Marketed By: Takeda Pharmaceuticals
- Major Indication: Hypoglycemia & Type 2 Diabetes
- Drug Class: PPAR-γ Activator - Thiazolidinedione (Glitazones)
- Date of FDA Approval (Patent Expiration): 1999 (2011)
- 2009 Sales: $2.4 Billion [1]
- Why You Should Care: It is the best selling drug to treat Diabetes and is the 10th best selling drug in the United States.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| Glitazone Comparison | |||||
|---|---|---|---|---|---|
| Parameter | Pioglitazone (Actos) | Rosiglitazone (Avandia) | |||
| Tmax (hr) | |||||
| Cmax (ng/ml) | |||||
| Bioavailability (%) | |||||
| Protein Binding (%) | 99 | 99 | |||
| T1/2 (hr) | 3-7 | 3-4 | |||
| AUC (ng/ml/hr) | |||||
| IC50 (nM) | |||||
| Equivalent Dosage (mg) | |||||
| Metabolism | Hepatic (CYP2C8) |
Hepatic (CYP2C8) | |||
Effectiveness and Side Effects
Effectiveness
Side Effects
Interesting Facts
The Jist
References
